Skin Autofluorescence Is Not Increased in Patients with Systemic Sclerosis PDF Print E-mail
Thursday, 01 March 2012 15:52
M. E. Hettema, H. Bootsma, R. Graaff, R. de Vries, C. G. M. Kallenberg, and A. J. Smit
Received 24 May 2011; Accepted 8 August 2011

Vascular involvement is a key factor in major manifestations of systemic sclerosis (SSc), such as Raynaud’s phenomenon (RP), myocardial dysfunction, pulmonary hypertension, and renal involvement. Microvascular involvement, in which endothelial injury is present, is the main characteristic of SSc. Oxidative stress has been suggested as a major player in the process of endothelial dysfunction found in SSc. Endothelial damage may be induced by oxygen free radicals and reactive nitrogen species, generated locally by the inflammatory process and by periods of tissue ischemia followed by postischaemic reperfusion. This socalled ischaemic-reperfusion injury can be seen in RP. Increased levels of antibodies against oxidised low-density lipoproteins (LDL) and increased serum levels of 8-isoprostane, being markers of oxidative stress, have, indeed, been observed in SSc.

Oxidative or carbonyl stress, leading to formation of so-called reactive carbonyl compounds, is an important source for the generation of so-called advanced glycation endproducts (AGEs). AGE generation as a result of oxidative stress has also been found in inflammatory diseases, such as rheumatoid arthritis and SLE.

Tissue autofluorescence (AF) is a marker of the accumulation of AGEs, validated in different patient groups and healthy controls. Therefore, we assessed AGE accumulation in patients with SSc and hypothesized that AGE accumulation is increased in patients with SSc compared to healthy controls based on the presence of oxidative stress and endothelial dysfunction in SSc. We related AGE accumulation to the presence of disease-related and traditional cardiovascular risk factors.

Continue reading the full article, by downloading it from the link provided below.

 
More articles :

» Orphan Drug Status Granted For Revimmune In Treatment of Systemic Sclerosis

, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to RevimmuneTM, the company's proprietary system-of-care based on high-dose administration of Cytoxan(R) (), for the treatment of two...

» The Role of Intravenous Immunoglobulin Preparations in the Treatment of Systemic Sclerosis

Marta Baleva and Krasimir NikolovReceived 12 June 2011; Revised 28 August 2011; Accepted 28 August 2011Scleroderma is progressive autoimmune disease associated with severe disability. The major underlying pathological process in scleroderma is...

» Dysexecutive Syndrome A Specific Pattern of Cognitive Impairment in Systemic Sclerosis

Systemic sclerosis (SSc), also called scleroderma, is a connective-tissue disorder characterized by obliterative microvascular lesions and diffuse interstitial fibrosis. SSc damages the small and medium-sized vessels serving the skin, joints...

» NeoStem Awarded Grant To Develop New Treatment for Skin Wounds In Scleroderma

NeoStem, as a leader in the emerging cellular therapy industry, announced that it had received an award under the Small Business Innovative Research Program of $147,765 for the “Development of Adult Pluripotent Very Small Embryonic Like (VSEL)...

» Anticentromere Antibody Positive Sjögren’s Syndrome: A Retrospective Descriptive Analysis

Introduction: A subgroup of patients with primary Sjögren’s Syndrome (SS) and positive anticentromere antibodies (ACA) were recognized as having features intermediate between SS and systemic sclerosis (SSc). Our goal was to describe this group...

» Exposure To Solvents A Health Risk

Exposure to solvents by medical laboratory workers may be a health risk according to a new study from the , Wellington just published in . "Our study of 341 medical laboratory workers indicates they are more likely to develop a condition called...